Evaluation of a novel vaginal bromocriptine mesylate formulation: a pilot study.
Because of the frequent side effects found with oral bromocriptine, we created two formulas of vaginal bromocriptine suppositories to compare with vaginal application of bromocriptine tablets. The formula containing bromocriptine and a releasing agent (Pluronic F127) showed an increased dissolution rate, 39-fold greater than that of the pure drug alone, and subsequently was effective in lowering serum prolactin.
Darwish
Atef M
AM
Department of Obstetrics and Gynaecology, Faculty of Medicine, Infertility Outpatient Clinic, Mother-Health Hospital, Assiut University, 71516 Assiut, Egypt. a_darwish@mailcity.com
Hafez
Ehsan
E
El-Gebali
Ibraheem
I
Hassan
Saher B
SB
D001971:Bromocriptine / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006727:Hormone Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy*; D017060:Patient Satisfaction; D010865:Pilot Projects; D013488:Suppositories
D006727:Hormone Antagonists; D013488:Suppositories; D001971:Bromocriptine